Skip to search formSkip to main contentSkip to account menu

Bextra

Known as: Pfizer brand of valdecoxib 
a kind of nonsteroidal anti-inflammatory drugs
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

valdecoxib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
Progress in COX-2 inhibitors: a journey so far.
The non-steroidal anti-inflammatory drugs (NSAIDs) are diverse group of compounds used for the treatment of inflammation, since… 
2009
2009
Pfizer settles largest ever fraud suit for off-label promotion
2007
2007
Successful treatment of cystoid macular edema with valdecoxib
Highly Cited
2005
Highly Cited
2005
Parecoxib, valdecoxib, and cardiovascular risk.
Selective inhibitors of cyclooxygenase (COX)-21 depress prostacyclin (PGI2) but not COX-1–derived thromboxane A2. The effects of… 
2005
2005
New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra)
Reason for posting: Coxibs, the class of NSAIDs that selectively inhibit cyclooxygenase 2 (COX-2), were designed to reduce joint… 
Highly Cited
2005
Highly Cited
2005
FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke
After three days of deliberation an advisory panel to the US Food and Drug Administration decided that the widely used cyclo… 
Highly Cited
2005
Highly Cited
2005
The use of nonsteroidal anti-inflammatory drugs (NSAIDs): a science advisory from the American Heart Association.
Recent clinical trial data have raised questions about the degree to which patients and their physicians should consider an… 
Highly Cited
2005
Highly Cited
2005
COX 2 inhibitors, traditional NSAIDs, and the heart
Adverse event data from clinical trials must inform decision making T hese are trying times for patients with chronic… 
Review
2005
Review
2005
Selective Cyclooxygenase-2 Inhibitors Development in Cardiovascular Medicine
At the end of September 2004, Merck & Co announced the voluntary withdrawal of rofecoxib (Vioxx) worldwide because of an… 
Highly Cited
2004
Highly Cited
2004
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
By optimizing binding to a selected target protein, modern drug research strives to develop safe and efficacious agents for the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)